Strategic Valuation of Match Making Strategies between Biotech and Pharmaceutical Companies
Date Issued
2007
Date
2007
Author(s)
Su, Ching-Tien
DOI
en-US
Abstract
Healthcare industry is possibly the most expensive service industry in the world. To cope with technology changes and innovation challenge, pharmaceutical companies have to engage R&D collaborations with biotechnology companies and develop co-opetition relationship with each other. The smaller biotech companies always have the dilemma to either license-out (to big pharma) or launch the product on their own during collaborative processes.
This thesis illustrates systematically those intrinsic driving forces underlying the co-developing relationship and maps out a strategic scheme for smaller biotech companies to maximize their potential value proposition in dealing with their pharmaceutical counterparts. The schematic model, which focuses on the new perspectives such as intrinsic and extrinsic factors from both biotech and pharmaceutical industries, could be used as an empirical tool in formulating corporate strategies. Finally, a case study using a new drug product pipeline from a Taiwan based biotech company demonstrates a potential best practice deducted from the above scheme.
Subjects
健康照護
生物科技
製藥
生命週期管理
產品組合管理
專案管理
鑑價
Healthcare
Biotechnology
Pharmaceutical
Product Pipeline
Lifecycle Management
Portfolio Management
Project Management
Valuation
Type
other
File(s)![Thumbnail Image]()
Loading...
Name
ntu-96-P93743025-1.pdf
Size
23.31 KB
Format
Adobe PDF
Checksum
(MD5):52f12595dfc4121890e1796354630ae6